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Abstract
Aims: Given that diabetes is associated with cognitive impairment and dementia 
in later life, we aimed to investigate the relationship between glycated haemo-
globin (HbA1c), diabetes and domain- specific neuropsychological performance in 
older adults.
Methods: Cross- sectional cohort study using data from the Trinity- Ulster- 
Department of Agriculture (TUDA) study. Participants underwent detailed cogni-
tive and neuropsychological assessment using the Mini- Mental State Examination 
(MMSE), Frontal Assessment Battery (FAB) and Repeatable Assessment for 
Neuropsychological Status (RBANS). Linear regression was used to assess as-
sociations between HbA1c, diabetes status and neuropsychological performance, 
with adjustment for important clinical covariates.
Results: Of 4938 older adults (74.1 ± 8.3 years; 66.9% female), 16.3% (n = 803) 
had diabetes (HbA1c ≥  6.5%; 48  mmol/mol), with prediabetes (HbA1c ≥  5.7%– 
6.4%; 39– 47 mmol/mol) present in 28.3% (n = 1395). Increasing HbA1c concentra-
tion was associated with poorer overall performance on the FAB [β: −0.01 (−0.02, 
−0.00); p = 0.04 per % increase] and RBANS [β = −0.66 (−1.19, −0.13); p = 0.02 
per % increase]. Increasing HbA1c was also associated with poorer performance 
on immediate memory, visuo- spatial, language and attention RBANS domains. 
Diabetes was associated poorer performance on neuropsychological tests of im-
mediate memory, language, visual- spatial and attention.
Conclusions: Both increasing HbA1c and the presence of diabetes were asso-
ciated with poorer cognitive and domain- specific performance in older adults. 
HbA1c, and not just diabetes status per se, may represent an important target in 
the promotion of optimal brain health in older adults.
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1  |  INTRODUCTION
Diabetes is one of the most potent risk factors for the de-
velopment of dementia in later life.1– 4 Recent estimates 
suggest that diabetes poses nearly as great a risk for 
developing dementia as APOE4 status, the most preva-
lent genetic risk factor for sporadic Alzheimer's Disease 
(AD).5 While the diabetes- dementia link has been well 
established, comparatively less research has investi-
gated the relationship between diabetes and specific do-
mains of cognitive function in older people. This may 
be particularly relevant in identifying individuals at risk 
who could benefit from early interventions aimed at 
the prevention of dementia. Such interventions, though 
successful in high- risk individuals, have not been typi-
cally assessed in those with hyperglycaemia and/or 
diabetes.6– 8
Glycated haemoglobin (HbA1c) reflects average glu-
cose concentrations over the preceding 3  months and 
has clinical utility not only in diabetes diagnosis but also 
in the identification of individuals at risk of diabetes.9,10 
Few studies have specifically explored the relationship be-
tween HbA1c and cognitive function, particularly in those 
without diabetes or in those with prediabetes, conditions 
which may represent an important target for early inter-
vention. Notably, in the ACCORD- MIND study, a 1% in-
crease in HbA1c was associated with significantly poorer 
performance in the Digit Symbol Substitution Test (DSST) 
and the Mini- Mental State Examination (MMSE).11 
Similarly, studies in those with diabetes have identified 
a significant relationship between hyperglycaemia and 
poorer performance in tests of perceptual speed and 
visuo- spatial tasks.12 Thus, elevated HbA1c may represent 
an important target for early intervention, rather than fo-
cussing on diabetes status alone.
Evidence is beginning to emerge from studies such 
as in the English Longitudinal Study of Ageing (ELSA) 
and the Health and Retirement Study (HRS) that HbA1c 
may be associated with poorer cognitive function in older 
adults independent of diabetes status.13,14 Similarly, some 
studies in patients without diabetes have demonstrated a 
relationship between greater HbA1c and poorer cognitive 
function.15 While such studies have identified significant 
associations with commonly used global tests of cognition, 
the relationship of HbA1c with more detailed measures of 
domain- specific neuropsychological function is less well 
explored and may be important in identifying older adults 
at greater risk of future cognitive decline.
The Trinity- Ulster- Department of Agriculture 
(TUDA) study recruited over 5000 older adults with-
out a diagnosis of dementia to undergo detailed health, 
metabolic and cognitive assessments. Previous research 
from this cohort has highlighted the importance of hy-
perglycaemia (above a certain cut- point) with metformin 
use as a potential predictor of cognitive dysfunction.16 
However, the relationship between increasing HbA1c and 
domain- specific cognitive performance in those with 
normoglycaemia, prediabetes or diabetes has not been 
assessed. The aim of the current study was to investigate 
the cross- sectional relationship of HbA1concentration 
with domain- specific cognitive function in TUDA 
participants.
2  |  METHODS
2.1 | Study design
The current study consisted of an analysis of data from 
the TUDA study which was conducted between 2008 and 
2012 (ClinicalTrials.gov identifier: NCT02664584) and has 
been described elsewhere.17– 19 Briefly, participants were 
recruited from general practise and hospital outpatient 
clinics in Northern Ireland and the Republic of Ireland. 
Inclusion criteria included age ≥60 years and not having 
an existing diagnosis of dementia. Participants were re-
cruited as part of three subcohorts: (i) cognitive subcohort: 
from geriatric medicine clinics/day hospital at St James's 
Hospital, Dublin; (ii) bone subcohort: participants with a 
diagnosis of osteopenia/osteoporosis (as per World Health 
Organisation criteria) from a specialist bone health ser-
vice at St James's Hospital, Dublin and (iii) hypertensive 
subcohort: individuals with a diagnosis of hypertension 
recruited from general practises in the catchment area of 
the Western and Northern Health and Social Care trusts in 
Northern Ireland. Ethical approval was obtained from the 
Office for Research Ethics Committees Northern Ireland 
(ref: 08/NIR03/113), and the Research Ethics Committee 
in St James's Hospital, Dublin, Ireland.
What’s new?
• Diabetes is a risk factor for dementia in later 
life, but the relationship between HbA1c and 
domain- specific neuropsychological perfor-
mance in older adults is less well explored.
• Increasing HbA1c concentration was associated 
with poorer overall and domain- specific neu-
ropsychological performance in older adults
• Similarly, diabetes was associated with poorer 
performance on immediate memory, visual- 
spatial, language and attention domains.
   | 3 of 10DYER et al.
2.2 | Health and lifestyle assessment
Comprehensive assessment of health, lifestyle and 
medical comorbidity was undertaken via a 90- min in-
terview. Weight (electronic scales from Brosch Direct 
Ltd.) and height (wall- mounted stadiometer from Seca 
Ltd.) were recorded in standard fashion. Participants 
were asked a series of questions on their medical history 
including diagnosis of diabetes, hypertension, ischae-
mic heart disease, atrial fibrillation, congestive cardiac 
failure and cerebrovascular disease (stroke or tran-
sient ischaemic attack). Participants were also asked 
about alcohol and smoking history and to provide a list 
of the current medications they were taking, coded as 
per the Anatomical Therapeutic Classification (ATC) 
System. A history of hypertension was defined as any 
known history of hypertension or being currently pre-
scribed medication used to treat hypertension (such as 
angiotensin- converting enzyme inhibitors, angiotensin 
receptor blockers, thiazide diuretrics). Hyperlipidaemia 
was considered to be a known history of the same or 
being prescribed lipid- lowering therapy.
2.3 | Blood sampling and analysis
Blood samples were obtained and processed within 4  h 
of collection. HbA1c was measured in both jurisdictions 
in participating hospital laboratories using the Bio- Rad 
Variant II Turbo analyser (Bio- Rad Laboratory Inc.), 
traceable to the International Federation for Clinical 
Chemistry (IFCC) reference method. Results are reported 
as both IFCC units in mmol/L and as Diabetes Control 
and Complications Trial (DCCT) units in %. Blood sam-
ples were additionally analysed for total cholesterol and 
total triglycerides (in mmol/L) in the hospital laboratories.
2.4 | Diabetes
Diabetes was defined by one or more of the following: 
(i) self- reported diagnosis of diabetes, (ii) use of dia-
betes medication (oral hypoglycaemic/insulin) or (iii) 
HbA1c ≥  48  mmol/L (6.5%). Prediabetes was defined as 
an HbA1c 39.0– 47.0  mmol/L (5.7%– 6.4%) without meet-
ing the criteria for diabetes (i.e. formal diagnosis or an-
tidiabetic medication as above) according to American 
Diabetes Association (ADA) Criteria.20 Diabetes medi-
cations were identified via the ATC Codes ‘A10A’ and 
‘A10B’ and ‘A10X’ referring to ‘insulins and analogues’, 
‘blood glucose- lowering drugs” and ‘other drugs used in 
diabetes’, respectively. Those who did not meet the crite-
ria for either prediabetes or diabetes were deemed to be 
‘normoglycaemic’.
2.5 | Cognitive assessment
Cognitive assessment was undertaken by trained asses-
sors in a standardised fashion at both study sites. The 
Mini- Mental State Examination (MMSE) was used as an 
assessment of global cognitive function and is the most 
widely used cognitive screening tool in health research 
and clinical practise.21  The Frontal Assessment Battery 
(FAB) tool was used to assess frontal lobe executive func-
tion and specifically in the areas of conceptualisation (as-
sessing similarities), mental flexibility (verbal fluency), 
motor programming (‘Luria’ test), resistance to interfer-
ence (conflicting instructions), inhibitory control (via a 
go- no- go paradigm) and environmental autonomy (pre-
hension behaviour). It is scored out of a total of 18.22 The 
Repeatable Battery for Assessment of Neuropsychological 
Status (RBANS) was used as a detailed neuropsychologi-
cal assessment of five cognitive domains, including imme-
diate memory (Index I), visual- spatial (Index II), language 
(Index III), attention (Index IV) and delayed memory 
(Index V), with each domain scored from 100.23  The 
RBANS was administered by trained assessors who un-
derwent identical training at each study site. Index scores 
were calculated in a standardised fashion in addition to a 
total score reflecting overall performance on the five do-
mains.23 Participants also underwent assessment for cur-
rent anxiety and depressive symptoms using the Hospital 
Anxiety and Depression Scale (HADS) and Centre for 
Epidemiological Studies Depression scale (CES- D), re-
spectively.24,25 Standard cut- offs were applied with a score 
of ≥16 indicating depression (CES- D) and a score of ≥11 
indicating anxiety (HADS).19
2.6 | Statistical analysis
All statistical analysis was conducted using STATA v. 15.0 
(STATACorp) with an alpha level of p < 0.05 considered 
statistically significant. Data were inspected for normal-
ity of distribution by examining Q- q plots and histograms. 
Data which were not normally distributed underwent nat-
ural log transformation. Descriptive statistics are reported 
as means with standard deviations, and medians with 
interquartile ranges as appropriate, in addition to pro-
portions and percentages. Between- group differences for 
those with diabetes, prediabetes and without either (i.e. 
normoglycaemic) were analysed using ANOVA, Kruskal– 
Wallis test and Chi- square tests as appropriate.
Linear regression was used to assess the relationship 
between HbA1c (in %) and cognitive function, with HbA1c 
(%) as the independent variable and cognitive test out-
come (total MMSE score, natural log- transformed FAB 
score, RBANS total and RBANS index scores) as the de-
pendent variable.










Age (years) 73.3 (8.4) 75.7 (8.1) 74.0 (7.8) <0.001
Sex (female) 1872 (68.3%) 998 (71.5%) 431 (53.7%) <0.001
Body mass index 26.9 (5.0) 28.5 (5.4) 30.4 (5.6%) <0.001
Waist– hip ratio 0.90 (0.1) 0.91 (0.1) 0.95 (0.1) <0.001
Education (years) 16.2 (3.0) 15.8 (2.9) 15.6 (2.7) <0.001
Smoking (current) 323 (11.8%) 181 (13.0%) 92 (11.5%) 0.12
Alcohol (current) 1681 (61.3%) 742 (53.2%) 387 (48.2%) <0.001
Systolic blood pressure 
(mmHg)
144.6 (21.1) 144.7 (21.1) 144.9 (21.4) 0.90
Diastolic blood pressure 
(mmHg)
79.1 (11.0) 78.0 (11.2) 76.2 (11.7) <0.001





Hypercholesterolaemia 1472 (53.7%) 889 (63.7%) 666 (82.9%) <0.001
Myocardial infarction 220 (8.0%) 148 (10.6%) 129 (16.1%) <0.001
Atrial fibrillation 319 (11.7%) 218 (15.6%) 117 (14.6%) <0.001
Ischaemic heart disease 375 (13.7%) 233 (16.7%) 195 (24.3%) <0.001
Cerebrovascular disease 346 (12.6%) 245 (17.6%) 162 (20.2%) <0.001
HbA1c (mmol/l) 36.1 (2.3) 41.8 (1.9) 54.7 (13.6) <0.001
HbA1c (%) 5.5% (0.2%) 6.0% (0.2%) 7.2% (1.3%) <0.001
MMSE score 27.2 (2.6) 26.9 (2.6) 26.8 (2.7) <0.001
FAB score 16 (14– 17) 16 (14– 17) 16 (14– 17) <0.001
RBANS 86.7 (17.2) 83.9 (16.9) 82.7 (15.6) <0.001
Index I score 
(immediate memory)
90.5 (17.8) 88.8 (17.7) 86.0 (16.9) <0.001
Index II score (visual 
spatial)
89.5 (20.3) 86.0 (19.3) 86.6 (19.4) <0.001
Index III score 
(language)
90.8 (13.0) 89.4 (13.8) 88.7 (12.7) <0.001
Index IV score 
(Attention)
89.5 (17.5) 86.8 (17.5) 85.2 (17.3) <0.001
Index V score (delayed 
memory)










GLP−1 Analogue 35 (5.4%)
DPP−4 inhibitor 117 (17.9%)
Note: Data presented as means with standard deviations in addition to proportions with percentages. 
Between- group differences were analysed using ANOVA, Kruskal– Wallis and Chi- square tests as 
appropriate.
Abbreviations: DPP- 4, Dipeptidylpeptidase 4; FAB, Frontal Assessment Battery; GLP- 1, Glucagon- Like 
Peptide 1; HbA1c, glycated haemoglobin; MMSE, Mini- Mental State Examination; RBANS, Repeatable 
Battery for Assessment of Neuropsychological Status.
T A B L E  1  Characteristics of TUDA 
Participants by diabetes status










































































































































































































































































































































































































































































































































































































































































































































































































































































































6 of 10 |   DYER et al.








pβ (CI) β (CI) β (CI) β (CI)
MMSE
Normoglycaemic 0 (Ref.) 0 (Ref.) 0 (Ref.) 0 (Ref.)
Prediabetes −0.28 (−0.45, 
−0.11)
0.001 −0.00 (−0.16, 
0.16)
0.98 0.02 (−0.14, 
0.18)
0.83 0.03 (−0.14, 
0.19)
0.68
Diabetes −0.31 (−0.52, 
−0.11)
0.003 −0.15 (−0.35, 
0.05)
0.14 −0.09 (−0.29, 
0.11)




Normoglycaemic 0 (Ref.) 0 (Ref.) 0 (Ref.) 0 (Ref.)
Prediabetes −0.03 (−0.04, 
−0.01)
0.001 −0.002 (−0.02, 
0.01)
0.73 −0.00 (−0.02, 
0.01)
0.82 0.00 (−0.01, 
0.02)
0.98
Diabetes −0.03 (−0.05, 
−0.01)
<0.001 −0.02 (−0.04, 
−0.00)
0.03 −0.02 (−0.04, 
0.00)




Normoglycaemic 0 (Ref.) 0 (Ref.) 0 (Ref.) 0 (Ref.)
Prediabetes −2.78 (−3.88, 
−1.67)
<0.001 −0.77 (−1.539, 
0.587)
0.12 −0.58 (−1.55, 
0.41)
0.25 −0.34 (−1.30, 
0.63)
0.49
Diabetes −4.06 (−5.42, 
−2.70)
<0.001 −2.26 (−3.49, 
−1.04)
0.001 −1.63 (−2.87, 
−0.39)
0.01 −1.23 (−2.46, 
0.00)
0.05
RBANS index I 
(immediate 
memory)
Normoglycaemic 0 (Ref.) 0 (Ref.) 0 (Ref.) 0 (Ref.)
Prediabetes −1.76 (−2.90, 
−0.63)
0.002 −0.61 (−1.69, 
0.47)
0.27 −0.40 (−1.49, 
0.68)
0.47 −0.24 (−1.31, 
0.83)
0.66
Diabetes −4.58 (−5.96, 
−3.20)
<0.001 −2.57 (−3.90, 
−1.22)
0.001 −1.91 (−3.28, 
−0.55)
0.01 −1.65 (−3.01, 
−0.29)
0.02
RBANS index II 
(visual spatial)
Normoglycaemic 0 (Ref.) 0 (Ref.) 0 (Ref.) 0 (Ref.)
Prediabetes −3.51 (−4.80, 
−2.21)
<0.001 −1.27 (−2.43, 
−0.11)
0.03 −1.17 (−2.33, 
−0.01)
0.05 −0.95 (−2.10, 
0.20)
0.11
Diabetes −2.94 (−4.53, 
−1.04)
<0.001 −2.33 (−3.78, 
−0.89)
0.002 −2.00 (−3.48, 
−0.53)
0.01 −1.71 (−3.18, 
−0.25)
0.02
RBANS index III 
(language)
Normoglycaemic 0 (Ref.) 0 (Ref.) 0 (Ref.) 0 (Ref.)
Prediabetes −1.41 (−2.25, 
−0.56)
0.001 −0.53 (−1.34, 
0.27)
0.19 −0.48 (−1.28, 
0.32)
0.25 −0.39 (−1.19, 
0.41)
0.34
Diabetes −2.13 (−3.17, 
−1.10)
<0.001 −1.52 (−2.52, 
−0.52)
0.003 −1.29 (−2.29, 
−0.27)
0.01 −1.10 (−2.11, 
−0.08)
0.03
RBANS index IV 
(attention)
Normoglycaemic 0 (Ref.) 0 (Ref.) 0 (Ref.) 0 (Ref.)
Prediabetes −2.66 (−3.80, 
−1.52)
<0.001 −0.65 (−1.67, 
0.37)
0.21 −0.53 (−1.55, 
0.49)
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In the first instance, the association was tested unad-
justed (Model 1) and then followed by adjustment for age, 
sex, body mass index, an education level (age finished 
formal education), family history of dementia and study 
subcohort (Model 2). Further adjustment accounted for 
cardiovascular risk factors which may impact on the re-
lationship between HbA1c and cognition including hy-
perlipidaemia, hypertension, a history of cardiovascular 
(composite of either ischaemic heart disease, previous 
myocardial infarction, atrial fibrillation or congestive 
cardiac failure) or cerebrovascular disease (composite of 
either previous transient ischaemic attack or previous 
stroke) (Model 3). Models were further adjusted for prob-
able anxiety and depression in addition to alcohol use and 
smoking status (Model 4).
For all linear analysis, residual vs fit plots were ex-
amined to ensure normal distribution of residuals and 
variance inflation factors computed for linear models to 
examine for multicollinearity. Results for all models are 
reported as beta coefficients (β) with the corresponding 
95% confidence interval (CI).
3  |  RESULTS
3.1 | Participant characteristics and 
diabetes prevalence
Of 5186 participants, those with missing data for HbA1c 
(n  =  171) and cognitive assessment (n  =  77) were ex-
cluded and the remaining 4938 participants included in 
the current analysis (mean age: 74.1  ±  8.3  years; 66.9% 
female). Participants with missing data were significantly 
younger (71.7  ±  7.5  years, t  =  −3.71, p  <  0.001) with a 
lower BMI (26.9 ± 5.8 vs. 27.9 ± 5.4, t = −2.4, p = 0.01) 
with a greater proportion of females (75% female; χ2 = 7.1, 
p  =  0.01) than included individuals. The prevalence of 
diabetes was 16.3% (n = 803) with prediabetes present in 
28.3% (n = 1395) as per the above criteria. Of those with 
diabetes, 81.3% (n  =  653) had a self- reported diagnosis 
with 18.7% (n = 150) diagnosed based on HbA1c. No par-
ticipants with a normal HbA1c and without a diagnosis 
of diabetes were taking glucose lowering medications. 
Detailed characteristics of participants by diabetes status 
are presented in Table 1.
Of those with diabetes, 55.2% (362/653) were pre-
scribed metformin, 33.3% (218/653) a sulfonylurea, 4.6% 
(30/653) a thiazolidinedione, 1.2% (8/653) a glucagon- like 
peptide 1 analogue, 5.4% (35/653) a dipeptidylpeptidase 
4 inhibitor and 17.9% (117/653) insulin. Of those with a 
known diagnosis of diabetes (n = 653), the mean duration 
of the disease was 9.3 ± 8.6 years. The mean HbA1c of all 
participants with diabetes was 54.7 mmol/L (±13.5)/7.4% 
(±1.3) (see Table 1).
3.2 | HbA1c, overall and doman- specific 
neuropsychological performance
Increasing HbA1c was associated with significantly 
poorer performance (in unadjusted models) on all three 
cognitive measures (MMSE, FAB, RBANS) as well 
as on indices of I– IV on the RBANS (Table  2). While 
some associations were attenuated after adjustment, 
increasing HbA1c remained significantly associated 








pβ (CI) β (CI) β (CI) β (CI)
Diabetes −4.39 (−5.80, 
−2.99)
<0.001 −2.56 (−3.84, 
−1.29)
0.001 −2.17 (−3.46, 
−0.88)






Normoglycaemic 0 (Ref.) 0 (Ref.) 0 (Ref.) 0 (Ref.)
Prediabetes −1.42 (−2.62, 
−0.21)
0.02 0.17 (−0.97, 
1.31)
0.77 0.43 (−0.71, 
1.57)
0.46 0.61 (−0.52, 
1.75)
0.29
Diabetes −1.91 (−3.38, 
−0.44)
0.01 −0.17 (−1.58, 
1.25)
0.82 0.61 (−0.84, 
2.05)
0.41 0.93 (−0.51, 
2.36)
0.21
Note: Linear models are presented both unadjusted (Model 1) and with adjustments made for age, sex, body mass index, level of education (years) and a family 
history of dementia (Model 2). Model 3 further adjusts for hypertension, hyperlipidaemia, cardiovascular and cerebrovascular disease. Model 4 further adjusts 
for alcohol and smoking status as well as screened anxiety and depression symptoms.
Abbreviations: lnFAB, log- transformed Fontal Assessment Battery; MMSE, Mini- Mental State Examination; RBANS, Repeatable Battery for Assessment of 
Neuropsychological Status.
T A B L E  3  (Continued)
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(−0.02, −0.00) per %, p = 0.04] and the RBANS [β: −0.66 
(−1.19, −0.13) per %, p = 0.03] scores in fully adjusted 
models. Additionally, increasing HbA1c was associated 
with poorer performance on immediate memory [β: 
−0.88 (−1.48, −0.29) per %, p = 0.004], visuo- spatial [β: 
−0.77 (−1.42, −0.13) per %, p = 0.02], language [β: −0.48 
(−0.93, −0.04) per %, p = 0.03] and attention [β: −0.89 
(−1.45, −0.32) per %, p  =  0.01] RBANS domains. Full 
results are presented in Table 2.
3.3 | Prediabetes, diabetes and cognitive 
performance
We further examined whether prediabetes or diabetes 
was associated with poorer cognitive performance com-
pared to normoglycaemic participants. While predia-
betes (vs normoglycaemia) was associated with poorer 
performance on the all three assessments in addition 
to indices I– IV of the RBANS, these associations were 
attenuated following robust covariate adjustment. 
Unadjusted, diabetes (vs. normoglycaemia) was associ-
ated with significantly poorer performance on the over-
all FAB [β: −0.03 (−0.04, −0.01), p = 0.001] and RBANS 
[β: −4.06 (−5.42, −2.70), p < 0.001] scores in addition 
to indices I– IV of the RBANS. While these associations 
were attenuated under fully adjusted models, the asso-
ciations between diabetes and poorer performance on 
immediate memory [β: −1.65 (−3.01, −0.29), p = 0.02], 
visual- spatial [β: −1.71 (−3.18, −0.25), p  =  0.02], lan-
guage [β: −1.10 (−2.11, −0.08), p = 0.03] and attention 
[β: −1.84 (−3.13, −0.56), p  =  0.01] domains persisted 
following robust covariate adjustment. Full results are 
given in Table 3.
4  |  DISCUSSION
In the current study of nearly 5000 older adults from 
the TUDA study, increasing HbA1c was associated with 
poorer overall cognitive performance on the FAB and 
RBANS. Additionally, increasing HbA1c was signifi-
cantly associated with poorer domain- specific cognitive 
performance on RBANS domains I (immediate mem-
ory), II (visual- spatial), III (language) and IV (attention). 
While diabetes was not associated with overall FAB and 
RBANS scores following covariate adjustment, diabetes 
was associated with poorer performance on immediate 
memory, visual- spatial, language and attention RBANS 
domains. These findings highlight the potential impor-
tance and value of HbA1c and diabetes as a target that 
could be addressed in promoting optimal brain health in 
older adults.
To date, previous research has focussed only on the 
association between diabetes or prediabetes and cogni-
tive function, with few studies specifically exploring the 
relationship with HbA1c. Furthermore, in studies exam-
ining the association between HbA1c and cognition, neu-
ropsychological assessments have typically been fewer 
and less detailed than in this current study.13– 15 In one of 
the most detailed studies to date in this area, Zheng et al. 
demonstrated that HbA1c concentration was inversely 
associated with global cognition, memory and executive 
function.13 The findings of the current study are thus in 
line with the previous research, adding important new 
evidence to support the association between HbA1c and 
cognitive performance. These findings are also in good 
agreement with the findings from other studies, such as 
those from the Health and Retirement Study (HRS) which 
identified a significant impact of HbA1c concentrations on 
episodic memory, as well as studies examining the impact 
of HbA1c on cognitive decline in older adults without di-
abetes.14,15 While our findings are largely confirmatory of 
these previous analyses, they add further evidence to sup-
port the potential of HbA1c as a modifiable risk factor to 
promote optimal brain health in older adults.
The current results demonstrating poorer domain- 
specific neuropsychological performance in those with di-
abetes are also consistent with previous reports that have 
shown the impact of diabetes on neuropsychological tests 
of attention and memory.26– 28  This association may be 
worthy of further research, particularly in younger adults 
with midlife diabetes who may be at risk of future cogni-
tive decline. Both the current study and the majority of the 
previous research linking hyperglycaemia, diabetes and 
cognitive function have been undertaken in older individu-
als. Recent studies have demonstrated cross- sectional rela-
tionships between diabetes and tests of neuropsychological 
function in midlife.29,30 Furthermore, studies should focus 
on HbA1c in midlife and longitudinal change in specific 
domains of cognitive function in order to identify individ-
uals who may be most at- risk of later decline. By exclud-
ing those with a known diagnosis of dementia, the TUDA 
study was designed to reflect both the normal range of 
cognitive function in ageing in addition to mild cognitive 
impairment. Thus, our sample may be biased to include in-
dividuals with better cognitive function than similarly aged 
individuals in more representative population studies.
One of the strengths of this study is the detailed na-
ture of cognitive tests used. Previous studies examining 
the impact of HbA1c on cognition have been limited by 
both fewer and less comprehensive cognitive testing, often 
relying only on global cognition measures or screening 
tests such as MMSE. The inclusion of a detailed neuro-
psychological battery of tests (using the RBANS) in the 
current study is a particular strength. This battery allowed 
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us not only to examine the relationship between HbA1c 
and global cognition but also the association in greater de-
tail by incorporating tests of specific cognitive domains. 
Furthermore, the current study was able to control for 
a large number of covariates and potential confounders 
including assessments of educational attainment, depres-
sion, anxiety and mood, and also a history of cardiovascu-
lar disease and other risk factors known to be associated 
with dementia risk.
The biggest limitation of the current study is the cross- 
sectional design, therefore no causality can be inferred 
from the results. Thus, the results of the current study 
cannot confirm whether increased HbA1c results in poorer 
cognitive performance. Importantly, the association may 
vary by age and could be time- or exposure- dependent, 
potentially only acting as a risk factor during a particular 
window of susceptibility. For instance, diabetes is known 
to act as a risk factor for dementia in midlife, but not nec-
essarily in later life.29,30 Future studies are needed to as-
sess individuals using sensitive neuropsychological tests 
earlier in life who would be followed up longitudinally 
to gauge the impact of HbA1c on a cognitive decline over 
time.
A further limitation of the current study again cen-
tres around its cross- sectional nature. No inference can 
be made as to the potential influence of duration of hy-
perglycaemia as we have no historical data on previous 
HbA1c or duration of undiagnosed diabetes or prediabe-
tes. Similarly, the current study had no data on other risk 
factors for poorer cognition in individuals with diabetes 
such as albuminuria and did not consider lifestyle risk fac-
tors such as exercise and diet, which are known to be im-
portant in the promotion of optimal brain health in older 
adults.6,7 Furthermore, it must be acknowledged that the 
effect sizes observed in the current study are rather small, 
particularly for the FAB. However, our findings add fur-
ther evidence to the potential utility of HbA1c and diabetes 
as an important factor in the optimal promotion of brain 
health in older adults, worthy of further study in a longi-
tudinal fashion, particularly in younger and middle- aged 
individuals with diabetes.
5  |  CONCLUSION
This study demonstrated a significant association between 
increasing HbA1c and poorer cognitive performance in a 
study of nearly 5000 older adults. The results indicate that 
regardless of diabetes status, increasing HbA1c is associ-
ated with poorer cognitive function. Importantly, these re-
sults suggest that HbA1c may be a risk factor for cognitive 
decline in older adults and might be an appropriate target 
for strategies used to promote brain health.
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